Akihiro Tsuda
Overview
Explore the profile of Akihiro Tsuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
387
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsuda A, Mori K, Uedono H, Nakatani S, Nagata Y, Kurajoh M, et al.
Hypertens Res
. 2024 Dec;
48(3):1115-1124.
PMID: 39663390
The definition of hyperfiltration, the main pathogenesis in renal impairment in obesity and diabetes mellitus, is uncertain. Glomerular filtration rate (GFR) declines physiologically with aging, and there is inaccuracy in...
2.
Nakatani S, Shoji T, Morioka F, Nakaya R, Ueda M, Uedono H, et al.
Nutrients
. 2024 Oct;
16(19).
PMID: 39408237
Background/objectives: Zinc is an essential microelement, and its deficiency is common in patients undergoing hemodialysis. However, the association between serum zinc and mortality in these patients remains unclear. The aim...
3.
Uedono H, Kurajoh M, Toi N, Tsuda A, Shinmaru K, Miki Y, et al.
Am J Hypertens
. 2024 May;
37(10):801-809.
PMID: 38776410
Background: In primary aldosteronism (PA), aldosterone could affect glomerular hemodynamics by elevating renal vascular resistance and glomerular capillary pressure. However, the relationship between plasma aldosterone concentrations (PAC) and glomerular hemodynamics...
4.
Tani H, Hirashio S, Tsuda A, Tachiyama Y, Hara S, Masaki T
CEN Case Rep
. 2024 Feb;
13(5):366-372.
PMID: 38416371
There is a close relationship between thyroid dysfunction and renal dysfunction. However, thyroid dysfunction can unfortunately result in inaccurate measurements of serum creatinine and cystatin C levels. The chronic decrease...
5.
Morioka F, Nakatani S, Mori K, Naganuma T, Yamasaki T, Uedono H, et al.
Intern Med
. 2024 Feb;
63(18):2537-2541.
PMID: 38346741
Thirteen years after kidney donation, a 70-year-old man was referred to a nephrologist because of proteinuria. The serum creatinine, albumin, and urinary protein levels were 2.39 mg/dL, 3.0 g/dL, and...
6.
Uedono H, Mori K, Nakatani S, Watanabe K, Nakaya R, Morioka F, et al.
Case Rep Nephrol Dial
. 2024 Jan;
14(1):1-9.
PMID: 38179179
Introduction: Alport syndrome (AS) is a hereditary, progressive kidney disease characterized by structural abnormalities and dysfunction of the glomerular basement membrane (GBM). AS is classified as X-linked, autosomal, and digenic....
7.
Nakatani S, Morioka F, Uedono H, Tsuda A, Mori K, Emoto M
CEN Case Rep
. 2023 Dec;
13(4):284-289.
PMID: 38117458
To date, there is insufficient evidence regarding use of sodium-glucose cotransporter-2 (SGLT2) inhibitors for patients with autosomal-dominant polycystic kidney disease (ADPKD), as such cases have been excluded from previous clinical...
8.
Morioka F, Nakatani S, Uedono H, Tsuda A, Mori K, Emoto M
J Clin Med
. 2023 Oct;
12(19).
PMID: 37834985
Treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors may have pleiotropic and beneficial effects in terms of ameliorating of risk factors for the progression of autosomal dominant polycystic kidney disease (ADPKD). However,...
9.
Hara A, Wada T, Muso E, Maruyama S, Kato S, Furuichi K, et al.
Blood Purif
. 2022 Dec;
52(4):373-381.
PMID: 36521435
Introduction: Treating diabetic nephropathy with low-density lipoprotein (LDL) apheresis reduces proteinuria and improves prognosis. However, its impact on patients' quality of life (QoL) is unclear. This study evaluated the effect...
10.
Morioka F, Nakatani S, Tsuda A, Mori K, Emoto M
CEN Case Rep
. 2022 Sep;
11(4):511-512.
PMID: 36114985
No abstract available.